Examinando por Autor "Rivera Chicaiza, Erika Johanna"
Mostrando 1 - 1 de 1
- Resultados por página
- Opciones de ordenación
Ítem Acceso Abierto Efectividad de la inmunoterapia con pembrolizumab versus inmunoterapia con pembrolizumab combinada con quimiorradiación en el cáncer de cérvix. Revisión sistemática(Universidad Católica de Cuenca., 2024) Rivera Chicaiza, Erika Johanna; Buenaño Rodríguez, Christian Eduardo; 0107239402Cervical cancer is a malignant neoplasm that originates in the cells of the cervix and is caused by a sexually transmitted infection of the human papillomavirus (HPV). It is a highly prevalent condition among women worldwide, requiring early diagnosis to improve treatment efficacy. Objective: To analyze the effectiveness of pembrolizumab immunotherapy versus pembrolizumab immunotherapy combined with chemoradiation in cervical cancer. Methodology: A qualitative systematic review of controlled clinical trials was conducted on literature reviews and systematic reviews in English and Spanish reporting the effectiveness of pembrolizumab immunotherapy versus pembrolizumab combined with chemoradiation in cervical cancer from 2016 to 2024. Results: Studies confirmed the effectiveness of pembrolizumab combined with chemoradiotherapy for cervical cancer, with overall survival rates increasing by more than 50% in patients treated with this combination. Adverse effects of pembrolizumab include fatigue, headaches, pneumonitis, hypothyroidism, neutropenia, anemia, and skin rash. Conclusions: Pembrolizumab shows greater effectiveness when combined with chemoradiation. Keywords: cervical cancer, pembrolizumab, immunotherapy, chemotherapy
